Oct 28, 2026 | Legal Compliance, News
Federal policy on compounded peptides just reached a pivotal milestone. On October 28, 2026, the Department of Health and Human Services (HHS) released an interim enforcement discretion policy governing the use of select peptide bulk drug substances in 503A...
Oct 21, 2026 | Legal Compliance, State-Specific Regulations, Technology & Privacy
On October 5, 2026, Nolla Health announced what it describes as the nation’s first AI system authorized to issue initial prescriptions. Debuting in Utah through its Nolla Derm app, the platform targets low-acuity dermatology, specifically mild to moderate acne,...
Oct 16, 2026 | Legal Compliance, News
The FDA may be preparing to ease restrictions on certain compounded peptides, potentially opening the door for medical spas, wellness clinics, and healthcare providers to offer treatments that have faced significant federal regulatory scrutiny in recent years. On...
Sep 29, 2026 | Legal Compliance
The U.S. Food and Drug Administration (FDA) issued a warning letter dated September 18, 2026 to Houston-based Empower Clinic Services, LLC d/b/a Empower Pharmacy and its CEO, Arta Shaun Noorian. Following a November 3 to 14, 2025 inspection of its Houston facility,...
Sep 16, 2026 | Legal Compliance, State-Specific Regulations, Technology & Privacy
California is updating its health care regulatory framework to address the rapid integration of artificial intelligence in clinical environments. With the passage of Assembly Bill No. 3030 (AB 3030), the state has established clear disclosure standards for health care...
Sep 2, 2026 | Legal Compliance, News, Risk Management
The U.S. Food and Drug Administration (FDA) has issued a detailed Warning Letter (CBER 26-726330) to Scottsdale, Arizona-based R3 Medical Companies, its affiliated entities Bello Bio, LLC and Regen Suppliers, LLC, and CEO David L. Greene, M.D. Following joint facility...
